Design a Western Blot for PDHA1

Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.

Isoforms · Four isoforms are listed. Relative to the canonical sequence, isoform 2 changes residue 96, isoform 3 lacks residues 170–200, and isoform 4 replaces residue 19 with a longer sequence. Isoform 3 or 4 could differ in size, but the features do not establish where either migrates. Check which isoforms the antibody can recognize before assigning extra bands.

PTM · UniProt lists phosphoserine at 232 by PDK1; at 293 and 300 by PDK1, PDK2, PDK3 and PDK4; and at 295 without a listed kinase. It also lists phosphotyrosine at 301. These are UniProt sequence coordinates; antibody or paper numbering may differ. Match the antibody to the stated site and numbering convention.

UniProt lists alternate acetylation or succinylation at lysines 63, 244 and 313; succinylation at 277 and 385; and acetylation at 321 and 336. These are UniProt sequence coordinates. A modification-specific signal needs a site-matched antibody; annotation alone does not predict a visible band shift.

PDHA1 has annotated phosphoserine and phosphotyrosine sites. For a site-specific antibody, compare blocking conditions using the antibody’s stated compatibility and select the condition with clear target signal and low background. Confirm the antibody’s site and numbering convention before interpreting the result.

Measure a site-specific phospho-PDHA1 signal alongside total PDHA1 if the goal is to assess phosphorylation relative to protein abundance. Specify the site: serines 232, 293, 295 and 300 and tyrosine 301 are annotated in UniProt coordinates. A total PDHA1 band alone cannot report occupancy at any one site.

Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.

Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.

Blocking · Standard workflow guidance: follow the A01906-4 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.

Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.

Interpretation · The predicted mass is 43.3 kDa, while the reported apparent band is approximately 40 kDa. PDHA1 is a mitochondrial matrix protein with a transit peptide keyword, but no cleavage site is supplied. These features do not establish the cause of the mass difference. Use the approximately 40 kDa observation as a guide and verify band identity experimentally.

Check antibody recognition against the four listed isoforms, especially isoform 3’s deletion of residues 170–200 and isoform 4’s replacement at residue 19. PDHA1 also has annotated phosphorylation, acetylation and succinylation. None of these annotations alone identifies an extra band or proves a visible shift; verify band identity before assigning a cause.